Oncolytics Biotech Inc. (ONCY)
After hours:
Oncolytics Biotech Inc.
322 11th Avenue SW
Suite 804
Calgary, AB T2R 0C5
Canada
403 670 7377
https://www.oncolyticsbiotech.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees:
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Matthew C. Coffey M.B.A., Ph.D. | President, CEO & Director | 787.77k | N/A | N/A |
| Mr. Kirk J. Look C.A., CA | Chief Financial Officer | 550.53k | N/A | N/A |
| Dr. Thomas C. Heineman M.D., Ph.D. | Chief Medical Officer | 606.43k | N/A | N/A |
| Ms. Allison Hagerman P.Eng., P.M.P. | Vice President of Product Development | 418.21k | N/A | N/A |
| Ms. Amy Goodowitz Levin | Vice President of Clinical Operations | 402.92k | N/A | N/A |
| Jon Patton | Director of Investor Relations & Communication | N/A | N/A | N/A |
| Mr. John Mark Lievonen BBA, C.M., FCA, LLD, MBA | Consultant | 18.88k | N/A | N/A |
Description
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Corporate Governance
Oncolytics Biotech Inc.’s ISS Governance QualityScore as of April 1, 2024 is 4. The pillar scores are Audit: 5; Board: 1; Shareholder Rights: 2; Compensation: 8.
